Core Viewpoint - The announcement presents the key operating data for the first half of 2025 for Shaanxi Kanghui Pharmaceutical Co., Ltd, highlighting a decline in revenue and profitability across various segments compared to the previous year [1][2]. Summary by Category Main Business Revenue by Industry - The total operating revenue for the company was 241.27 million yuan, a decrease of 7.24% compared to the previous year. The operating cost was 178.51 million yuan, which increased by 1.79%, resulting in a gross margin of 26.01%, down by 6.57% [2][3]. Main Business Revenue by Product Use - The revenue breakdown by product categories shows: - Gynecology: Revenue of 16.97 million yuan, down 18.36% year-on-year, with a gross margin of 52.99% - Respiratory and Cold: Revenue of 19.59 million yuan, down 16.12%, with a gross margin of 32.36% - Dermatology: Revenue of 32.26 million yuan, down 14.07%, with a gross margin of 67.96% - Orthopedics: Revenue of 15.47 million yuan, up 11.01%, with a gross margin of 40.99% - Others: Revenue of 32.62 million yuan, up 84.78%, with a gross margin of 48.72% - Traditional Chinese Medicine: Revenue of 14.26 million yuan, down 44.26%, with a negative gross margin of -2.96% - Pharmaceutical Intermediates: Revenue of 18.30 million yuan, up 906.55%, with a negative gross margin of -60.68% - Pharmaceutical Distribution: Revenue of 91.80 million yuan, down 23.14%, with a gross margin of 16.12% [2][3]. Main Business Revenue by Region - The revenue by region indicates: - Northeast: 9.71 million yuan, down 28.96% - North China: 24.29 million yuan, down 0.25% - East China: 45.14 million yuan, up 4.78% - South China: 16.91 million yuan, down 17.46% - Central China: 22.46 million yuan, down 1.64% - Northwest: 101.06 million yuan, up 10.12% - Southwest: 21.71 million yuan, down 50.58% [3].

证券代码：603139 证券简称：康惠制药 公告编号：2025-053 陕西康惠制药股份有限公司 关于2025年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年半年度报告披露工作的重要提醒》相关要求，现将公司 2025 年半年度主要经营数据披露如下： 单位：万元 项 目 营业收入 营业成本 毛利率（%） 营业收入比上 年增减（%） 营业成本比上 年增减（%） 毛利率比上 年增减(%) 妇科类 1,696.76 797.63 52.99 -18.36 -3.78 -7.12 呼吸感冒类 1,959.29 1,325.23 32.36 -16.12 -4.40 -8.29 皮肤科类 3,226.09 1,033.64 67.96 -14.07 -20.65 2.66 骨科类 1,547.02 912.91 40.99 11.01 49.94 -15.32 其他 3,262.43 1,673.08 48.72 84.7 ...

Core Viewpoint - New Tian Pharmaceutical continues to face declining performance in the first half of the year, with both revenue and net profit experiencing significant drops, primarily due to rising raw material costs and a noticeable decrease in product sales [2][4]. Financial Performance - The company reported a revenue of approximately 358 million yuan, a year-on-year decrease of 18.88% [4]. - Net profit attributed to shareholders was about 5.77 million yuan, down 80.99% year-on-year [4]. - The sales of gynecological products, which account for over 70% of revenue, fell by 16.61% [4][5]. Product Sales Breakdown - Gynecological products generated approximately 266 million yuan, representing a 16.61% decline [5]. - Urological products saw a revenue drop of 26.8%, totaling around 61 million yuan [5]. - Revenue from heat-clearing and detoxifying products decreased by 23.04%, amounting to approximately 28 million yuan [5]. - Other product categories experienced a 7% increase in revenue, totaling about 3.61 million yuan, but this only accounted for 1.01% of total revenue [4][5]. Cost and Expense Management - Rising raw material prices have been a persistent issue, with raw material costs accounting for 58.35% of total costs in 2023 [7]. - The company has been actively reducing sales expenses, with a 17.79% decrease in 2023 and a 15.06% decrease in 2024 [10]. - In the first half of 2025, sales expenses were approximately 159 million yuan, down 11.61% year-on-year [10]. Regulatory and Ethical Concerns - New Tian Pharmaceutical's subsidiary faced allegations of commercial bribery, which has led to increased scrutiny and pressure on sales strategies [9]. - The company has acknowledged the situation but has not provided detailed public comments on the allegations [9].

陕西康惠制药股份有限公司 关于2025年一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引等法律法规的要 求，现将公司 2025 年一季度主要经营数据披露如下： 证券代码：603139 证券简称：康惠制药 公告编号：2025-027 二、报告期内，公司主营业务收入按产品用途经营情况如下： 单位：万元 本公告之经营数据未经审计，提醒投资者审慎使用上述数据。 陕西康惠制药股份有限公司董事会 2025 年 04 月 29 日 项 目 营业收入 营业成本 毛利率（%） 营业收入比上 年增减（%） 营业成本比上 年增减（%） 毛利率比上 年增减(%) 妇科类 622.10 284.20 54.32 -13.08 93.19 -25.13 呼吸感冒类 1,059.83 759.46 28.34 -16.98 44.89 -30.6 皮肤科类 1,608.24 523.94 67.42 -9.51 -21.10 4.79 骨科类 663.13 382.90 42.26 ...